Healthcare Industry News: Gamma Knife
News Release - July 3, 2006
Elekta Selected to Upgrade and Expand the Cancer Treatment Facilities at Odense University Hospital in DenmarkSTOCKHOLM, Sweden--(HSMN NewsFeed)--July 3, 2006--Elekta (STO:EKTAB) today announced a multiple systems order from one of the leading Danish radiation clinics at Odense University Hospital, comprising several highly advanced medical linear accelerators including two Elekta Synergy® units. In conjunction, the clinic will also install an oncology information management system from IMPAC Medical Systems, an Elekta company. In total, these orders are valued at over DKK 46 million.
Elekta Synergy, the world-leading clinical solution for image guided radiation therapy (IGRT) and intensity modulated radiation therapy (IMRT), will allow the clinicians to visualize the target as a three dimensional volume, as well as surrounding anatomy and organs at risk, at the time of treatment, enabling more aggressive treatment of tumors with increased precision and accuracy while minimizing the risk of damage to surrounding healthy tissue.
The concept of IGRT is rapidly gaining clinical acceptance all over the world and Elekta Synergy is being established as the reference system for this more precise and accurate method for radiating cancer tumors. When it was time for the clinic at Odense University Hospital to upgrade and expand its technology for radiation therapy they turned to Elekta. Elekta was chosen after an extensive vendor evaluation.
In addition Elekta will provide the hospital with an Elekta Synergy Platform, a linear accelerator that is prepared to be upgraded to a full IGRT linac in the future. One of the hospital's current linear accelerators will also be upgraded by Elekta.
"After visiting numerous clinics that have IGRT solutions up and running, we decided that Elekta Synergy best meet our high set of criteria, another important reason was that Elekta's solution is very well established and has been proven clinically at so many sites throughout the world, more than any other systems," says Knud Aage Werenberg Chef Physicist at the radiation therapy clinic at Odense University Hospital, and continues "we are also pleased that Elekta can provide us with a software system from IMPAC, that will help us to work more efficient and effectively, which will benefit our patients."
The integrated software information management system from IMPAC helps to improve overall treatment and practice management across the spectrum of cancer care by streamlining diagnostic and treatment information. The system also allows the clinic to integrate the operations and treatment process on linear accelerators from different suppliers. The IMPAC system was chosen following a wide-ranging search for a new cancer information management system.
"We have been working with the clinic at Odense University Hospital for many years and we are very pleased that they chose a solution from Elekta when they took the next step in upgrading and expanding their radiation therapy facility. It's yet another proof of Elekta's leading position in advanced clinical solutions for cancer treatment and shows that what Elekta can offer is very well adapted to today's customer demand," summarizes Lennart Ward, Ph.D., Business Unit Manager Nordic & Baltic countries at Elekta.
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.
Elekta's systems and solutions are used at over 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
With approx. 1850 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.